Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 126

1.

Remission Of Non-Infectious Anterior Scleritis: Incidence And Predictive Factors.

Kempen JH, Pistilli M, Begum H, Fitzgerald TD, Liesegang TL, Payal A, Zebardast N, Bhatt NP, Foster CS, Jabs DA, Levy-Clarke GA, Nussenblatt RB, Rosenbaum JT, Sen HN, Suhler EB, Thorne JE.

Am J Ophthalmol. 2019 Apr 2. pii: S0002-9394(19)30134-5. doi: 10.1016/j.ajo.2019.03.024. [Epub ahead of print]

PMID:
30951689
2.

Techniques for improving ophthalmic studies performed on administrative databases.

Borkar DS, Sobrin L, Hubbard RA, Kempen JH, VanderBeek BL.

Ophthalmic Epidemiol. 2019 Jun;26(3):147-149. doi: 10.1080/09286586.2018.1554160. Epub 2018 Dec 6. No abstract available.

PMID:
30521404
3.

Prevalence and causes of blindness and vision impairment: magnitude, temporal trends and projections in South and Central Asia.

Nangia V, Jonas JB, George R, Lingam V, Ellwein L, Cicinelli MV, Das A, Flaxman SR, Keeffe JE, Kempen JH, Leasher J, Limburg H, Naidoo K, Pesudovs K, Resnikoff S, Silvester AJ, Tahhan N, Taylor HR, Wong TY, Bourne RRA; Vision Loss Expert Group of the Global Burden of Disease Study.

Br J Ophthalmol. 2019 Jul;103(7):871-877. doi: 10.1136/bjophthalmol-2018-312292. Epub 2018 Nov 8.

PMID:
30409914
4.

Periocular Triamcinolone vs. Intravitreal Triamcinolone vs. Intravitreal Dexamethasone Implant for the Treatment of Uveitic Macular Edema: The PeriOcular vs. INTravitreal corticosteroids for uveitic macular edema (POINT) Trial.

Thorne JE, Sugar EA, Holbrook JT, Burke AE, Altaweel MM, Vitale AT, Acharya NR, Kempen JH, Jabs DA; Multicenter Uveitis Steroid Treatment Trial Research Group.

Ophthalmology. 2019 Feb;126(2):283-295. doi: 10.1016/j.ophtha.2018.08.021. Epub 2018 Sep 27.

PMID:
30269924
5.

Fluorometholone 0.1% as Ancillary Therapy for Trachomatous Trichiasis Surgery: Randomized Clinical Trial.

Kempen JH, Tekle-Haimanot R, Hunduma L, Alemayehu M, Pistilli M, Abashawl A, Lawrence SD, Alemayehu W.

Am J Ophthalmol. 2019 Jan;197:145-155. doi: 10.1016/j.ajo.2018.09.017. Epub 2018 Sep 27.

PMID:
30267699
6.

Prevalence and causes of vision loss in South-east Asia and Oceania in 2015: magnitude, temporal trends and projections.

Keeffe JE, Casson RJ, Pesudovs K, Taylor HR, Cicinelli MV, Das A, Flaxman SR, Jonas JB, Kempen JH, Leasher J, Limburg H, Naidoo K, Silvester AJ, Stevens GA, Tahhan N, Wong TY, Resnikoff S, Bourne RRA; Vision Loss Expert Group of the Global Burden of Disease Study.

Br J Ophthalmol. 2019 Jul;103(7):878-884. doi: 10.1136/bjophthalmol-2018-311946. Epub 2018 Sep 12.

PMID:
30209084
7.

Prevalence and causes of vision loss in North Africa and Middle East in 2015: magnitude, temporal trends and projections.

Kahloun R, Khairallah M, Resnikoff S, Cicinelli MV, Flaxman SR, Das A, Jonas JB, Keeffe JE, Kempen JH, Leasher J, Limburg H, Naidoo K, Pesudovs K, Silvester AJ, Tahhan N, Taylor HR, Wong TY, Bourne RRA; Vision Loss Expert Group of the Global Burden of Disease Study.

Br J Ophthalmol. 2019 Jul;103(7):863-870. doi: 10.1136/bjophthalmol-2018-312068. Epub 2018 Sep 12.

PMID:
30209082
8.

Diabetic Retinopathy in Hispanics: A Perspective on Disease Burden.

Mora N, Kempen JH, Sobrin L.

Am J Ophthalmol. 2018 Dec;196:xviii-xxiv. doi: 10.1016/j.ajo.2018.08.021. Epub 2018 Aug 20. No abstract available.

PMID:
30138600
9.

Iontophoretic delivery of dexamethasone phosphate for non-infectious, non-necrotising anterior scleritis, dose-finding clinical trial.

O'Neil EC, Huang J, Suhler EB, Dunn JP Jr, Perez VL, Gritz DC, McWilliams K, Peskin E, Ying GS, Bunya VY, Maguire MG, Kempen JH.

Br J Ophthalmol. 2018 Aug;102(8):1011-1013. doi: 10.1136/bjophthalmol-2017-311610. Epub 2018 Apr 17.

PMID:
29666122
10.

Association of Hypovitaminosis D With Increased Risk of Uveitis in a Large Health Care Claims Database.

Sobrin L, Stanwyck LK, Pan W, Hubbard RA, Kempen JH, VanderBeek BL.

JAMA Ophthalmol. 2018 May 1;136(5):548-552. doi: 10.1001/jamaophthalmol.2018.0642.

11.

Prevalence and causes of vision loss in high-income countries and in Eastern and Central Europe in 2015: magnitude, temporal trends and projections.

Bourne RRA, Jonas JB, Bron AM, Cicinelli MV, Das A, Flaxman SR, Friedman DS, Keeffe JE, Kempen JH, Leasher J, Limburg H, Naidoo K, Pesudovs K, Peto T, Saadine J, Silvester AJ, Tahhan N, Taylor HR, Varma R, Wong TY, Resnikoff S; Vision Loss Expert Group of the Global Burden of Disease Study.

Br J Ophthalmol. 2018 May;102(5):575-585. doi: 10.1136/bjophthalmol-2017-311258. Epub 2018 Mar 15.

12.

Difluprednate 0.05% versus Prednisolone Acetate 1% for Endogenous Anterior Uveitis: Pooled Efficacy Analysis of Two Phase 3 Studies.

Sheppard JD, Foster CS, Toyos MM, Markwardt K, Da Vanzo R, Flynn TE, Kempen JH.

Ocul Immunol Inflamm. 2019;27(3):484-496. doi: 10.1080/09273948.2017.1407433. Epub 2017 Dec 20.

PMID:
29260952
13.

Authors Reply to Letter to the Editor- In Response to: Comment on Durrani et al.'s "Adalimumab for Ocular Inflammation".

Durrani K, Kempen JH, Foster CS; Systemic Immunosuppressive Therapy for Eye Diseases (SITE) Research Group.

Ocul Immunol Inflamm. 2019;27(1):71. doi: 10.1080/09273948.2017.1379545. Epub 2017 Oct 18. No abstract available.

PMID:
29043914
14.

Global causes of blindness and distance vision impairment 1990-2020: a systematic review and meta-analysis.

Flaxman SR, Bourne RRA, Resnikoff S, Ackland P, Braithwaite T, Cicinelli MV, Das A, Jonas JB, Keeffe J, Kempen JH, Leasher J, Limburg H, Naidoo K, Pesudovs K, Silvester A, Stevens GA, Tahhan N, Wong TY, Taylor HR; Vision Loss Expert Group of the Global Burden of Disease Study.

Lancet Glob Health. 2017 Dec;5(12):e1221-e1234. doi: 10.1016/S2214-109X(17)30393-5. Epub 2017 Oct 11. Review.

15.

Magnitude, temporal trends, and projections of the global prevalence of blindness and distance and near vision impairment: a systematic review and meta-analysis.

Bourne RRA, Flaxman SR, Braithwaite T, Cicinelli MV, Das A, Jonas JB, Keeffe J, Kempen JH, Leasher J, Limburg H, Naidoo K, Pesudovs K, Resnikoff S, Silvester A, Stevens GA, Tahhan N, Wong TY, Taylor HR; Vision Loss Expert Group.

Lancet Glob Health. 2017 Sep;5(9):e888-e897. doi: 10.1016/S2214-109X(17)30293-0. Epub 2017 Aug 2. Review.

16.

Association Between Long-Lasting Intravitreous Fluocinolone Acetonide Implant vs Systemic Anti-inflammatory Therapy and Visual Acuity at 7 Years Among Patients With Intermediate, Posterior, or Panuveitis.

Writing Committee for the Multicenter Uveitis Steroid Treatment (MUST) Trial and Follow-up Study Research Group, Kempen JH, Altaweel MM, Holbrook JT, Sugar EA, Thorne JE, Jabs DA.

JAMA. 2017 May 16;317(19):1993-2005. doi: 10.1001/jama.2017.5103.

17.

Risk of Ocular Hypertension in Adults with Noninfectious Uveitis.

Daniel E, Pistilli M, Kothari S, Khachatryan N, Kaçmaz RO, Gangaputra SS, Sen HN, Suhler EB, Thorne JE, Foster CS, Jabs DA, Nussenblatt RB, Rosenbaum JT, Levy-Clarke GA, Bhatt NP, Kempen JH; Systemic Immunosuppressive Therapy for Eye Diseases Research Group.

Ophthalmology. 2017 Aug;124(8):1196-1208. doi: 10.1016/j.ophtha.2017.03.041. Epub 2017 Apr 19.

18.

Morphological assessment of the retina in uveitis.

Altaweel MM, Gangaputra SS, Thorne JE, Dunn JP, Elner SG, Jaffe GJ, Kim RY, Rao PK, Reed SB, Kempen JH; MUST Research Group.

J Ophthalmic Inflamm Infect. 2016 Dec;6(1):33. doi: 10.1186/s12348-016-0103-2. Epub 2016 Sep 9.

19.

Adalimumab for Ocular Inflammation.

Durrani K, Kempen JH, Ying GS, Kacmaz RO, Artornsombudh P, Rosenbaum JT, Suhler EB, Thorne JE, Jabs DA, Levy-Clarke GA, Nussenblatt RB, Foster CS Md Facs, Systemic Immunosuppressive Therapy For Eye Diseases Site Research Group.

Ocul Immunol Inflamm. 2017 Jun;25(3):405-412. doi: 10.3109/09273948.2015.1134581. Epub 2016 Mar 22.

20.

Remission of Intermediate Uveitis: Incidence and Predictive Factors.

Kempen JH, Gewaily DY, Newcomb CW, Liesegang TL, Kaçmaz RO, Levy-Clarke GA, Nussenblatt RB, Rosenbaum JT, Sen HN, Suhler EB, Thorne JE, Foster CS, Jabs DA, Payal A, Fitzgerald TD; Systemic Immunosuppressive Therapy for Eye Diseases (SITE) Research Group.

Am J Ophthalmol. 2016 Apr;164:110-7.e2. doi: 10.1016/j.ajo.2015.12.034. Epub 2016 Jan 6.

21.

Risk of Retinal Neovascularization in Cases of Uveitis.

Patel AK, Newcomb CW, Liesegang TL, Pujari SS, Suhler EB, Thorne JE, Foster CS, Jabs DA, Levy-Clarke GA, Nussenblatt RB, Rosenbaum JT, Sen HN, Artornsombudh P, Kothari S, Kempen JH; Systemic Immunosuppressive Therapy for Eye Diseases Research Group.

Ophthalmology. 2016 Mar;123(3):646-54. doi: 10.1016/j.ophtha.2015.10.056. Epub 2015 Dec 11.

22.

Acute onset anterior uveitis after darbepoetin alfa infusion.

Li J, Orlin SE, Revere KE, Kempen JH.

J Ophthalmic Inflamm Infect. 2015 Dec;5(1):31. doi: 10.1186/s12348-015-0061-0. Epub 2015 Oct 26.

23.

Cataract Surgery Outcomes in Uveitis: The Multicenter Uveitis Steroid Treatment Trial.

Sen HN, Abreu FM, Louis TA, Sugar EA, Altaweel MM, Elner SG, Holbrook JT, Jabs DA, Kim RY, Kempen JH; Multicenter Uveitis Steroid Treatment (MUST) Trial and Follow-up Study Research Group.

Ophthalmology. 2016 Jan;123(1):183-90. doi: 10.1016/j.ophtha.2015.09.022. Epub 2015 Oct 20.

24.

Factors Predicting Visual Acuity Outcome in Intermediate, Posterior, and Panuveitis: The Multicenter Uveitis Steroid Treatment (MUST) Trial.

Kempen JH, Van Natta ML, Altaweel MM, Dunn JP, Jabs DA, Lightman SL, Thorne JE, Holbrook JT; Multicenter Uveitis Steroid Treatment (MUST) Trial Research Group.

Am J Ophthalmol. 2015 Dec;160(6):1133-1141.e9. doi: 10.1016/j.ajo.2015.09.017. Epub 2015 Sep 18.

25.

Benefits of Systemic Anti-inflammatory Therapy versus Fluocinolone Acetonide Intraocular Implant for Intermediate Uveitis, Posterior Uveitis, and Panuveitis: Fifty-four-Month Results of the Multicenter Uveitis Steroid Treatment (MUST) Trial and Follow-up Study.

Multicenter Uveitis Steroid Treatment (MUST) Trial Research Group, Kempen JH, Altaweel MM, Drye LT, Holbrook JT, Jabs DA, Sugar EA, Thorne JE.

Ophthalmology. 2015 Oct;122(10):1967-75. doi: 10.1016/j.ophtha.2015.06.042. Epub 2015 Aug 20.

26.

The Risk of Intraocular Pressure Elevation in Pediatric Noninfectious Uveitis.

Kothari S, Foster CS, Pistilli M, Liesegang TL, Daniel E, Sen HN, Suhler EB, Thorne JE, Jabs DA, Levy-Clarke GA, Nussenblatt RB, Rosenbaum JT, Lawrence SD, Kempen JH; Systemic Immunosuppressive Therapy for Eye Diseases Research Group.

Ophthalmology. 2015 Oct;122(10):1987-2001. doi: 10.1016/j.ophtha.2015.06.041. Epub 2015 Jul 30.

27.

Design and Interpretation of Clinic-Based Studies in Uveitis.

Cunningham ET Jr, Acharya N, Kempen JH, Zierhut M.

Ocul Immunol Inflamm. 2015 Aug;23(4):267-270. doi: 10.3109/09273948.2015.1074028. No abstract available.

PMID:
29265967
28.

Pattern of Pediatric Uveitis Seen at a Tertiary Referral Center from India.

Ganesh SK, Bala A, Biswas J, Ahmed AS, Kempen JH.

Ocul Immunol Inflamm. 2016 Aug;24(4):402-9. doi: 10.3109/09273948.2015.1012298. Epub 2015 Jul 14.

PMID:
26171572
29.

Demand for Tertiary Eye Care Services in Developing Countries.

Subburaman GB, Hariharan L, Ravilla TD, Ravilla RD, Kempen JH.

Am J Ophthalmol. 2015 Oct;160(4):619-27.e1. doi: 10.1016/j.ajo.2015.06.005. Epub 2015 Jun 19.

PMID:
26095262
30.

Cataract surgery in patients with uveitis.

Mehta S, Kempen JH.

Int Ophthalmol Clin. 2015 Summer;55(3):133-9. doi: 10.1097/IIO.0000000000000078. Review. No abstract available.

PMID:
26035765
31.

Uveitis Reactivation in Children Treated With Tumor Necrosis Factor Alpha Inhibitors.

Lerman MA, Lewen MD, Kempen JH, Mills MD.

Am J Ophthalmol. 2015 Jul;160(1):193-200.e1. doi: 10.1016/j.ajo.2015.04.016. Epub 2015 Apr 17.

32.

Immunosuppressive therapy and cancer risk in ocular inflammation patients: fresh evidence and more questions.

Khachatryan N, Kempen JH.

Ophthalmology. 2015 Feb;122(2):219-21. doi: 10.1016/j.ophtha.2014.11.023. No abstract available.

PMID:
25618424
33.

Immune markers predictive of neuropsychiatric symptoms in HIV-infected youth.

McGuire JL, Kempen JH, Localio R, Ellenberg JH, Douglas SD.

Clin Vaccine Immunol. 2015 Jan;22(1):27-36. doi: 10.1128/CVI.00463-14. Epub 2014 Oct 29.

34.

Risk of cataract among subjects with acquired immune deficiency syndrome free of ocular opportunistic infections.

Kempen JH, Sugar EA, Varma R, Dunn JP, Heinemann MH, Jabs DA, Lyon AT, Lewis RA; Studies of Ocular Complications of AIDS Research Group.

Ophthalmology. 2014 Dec;121(12):2317-24. doi: 10.1016/j.ophtha.2014.06.014. Epub 2014 Aug 8.

35.

Ocular toxicity in BRAF mutant cutaneous melanoma patients treated with vemurafenib.

Choe CH, McArthur GA, Caro I, Kempen JH, Amaravadi RK.

Am J Ophthalmol. 2014 Oct;158(4):831-837.e2. doi: 10.1016/j.ajo.2014.07.003. Epub 2014 Jul 15.

PMID:
25036880
36.

Periocular corticosteroid injections in uveitis: effects and complications.

Sen HN, Vitale S, Gangaputra SS, Nussenblatt RB, Liesegang TL, Levy-Clarke GA, Rosenbaum JT, Suhler EB, Thorne JE, Foster CS, Jabs DA, Kempen JH.

Ophthalmology. 2014 Nov;121(11):2275-86. doi: 10.1016/j.ophtha.2014.05.021. Epub 2014 Jul 11.

37.

Outcomes of cataract surgery in patients with uveitis: a systematic review and meta-analysis.

Mehta S, Linton MM, Kempen JH.

Am J Ophthalmol. 2014 Oct;158(4):676-692.e7. doi: 10.1016/j.ajo.2014.06.018. Epub 2014 Jun 28. Review.

PMID:
24983790
38.

Cost-effectiveness of fluocinolone acetonide implant versus systemic therapy for noninfectious intermediate, posterior, and panuveitis.

Multicenter Uveitis Steroid Treatment (MUST) Trial Research Group, Sugar EA, Holbrook JT, Kempen JH, Burke AE, Drye LT, Thorne JE, Louis TA, Jabs DA, Altaweel MM, Frick KD.

Ophthalmology. 2014 Oct;121(10):1855-62. doi: 10.1016/j.ophtha.2014.04.022. Epub 2014 Jun 5.

39.

Risk of retinal tear or detachment with oral fluoroquinolone use: a cohort study.

Eftekhari K, Ghodasra DH, Haynes K, Chen J, Kempen JH, VanderBeek BL.

Pharmacoepidemiol Drug Saf. 2014 Jul;23(7):745-52. doi: 10.1002/pds.3623. Epub 2014 Apr 22.

40.

Interobserver agreement in clinical grading of vitreous haze using alternative grading scales.

Hornbeak DM, Payal A, Pistilli M, Biswas J, Ganesh SK, Gupta V, Rathinam SR, Davis JL, Kempen JH.

Ophthalmology. 2014 Aug;121(8):1643-8. doi: 10.1016/j.ophtha.2014.02.018. Epub 2014 Mar 31.

41.

Difluprednate 0.05% versus prednisolone acetate 1% for endogenous anterior uveitis: a phase III, multicenter, randomized study.

Sheppard JD, Toyos MM, Kempen JH, Kaur P, Foster CS.

Invest Ophthalmol Vis Sci. 2014 May 6;55(5):2993-3002. doi: 10.1167/iovs.13-12660.

42.

Factors predictive of remission of new-onset anterior uveitis.

Artornsombudh P, Pistilli M, Foster CS, Pujari SS, Gangaputra SS, Jabs DA, Levy-Clarke GA, Nussenblatt RB, Rosenbaum JT, Suhler EB, Thorne JE, Kempen JH.

Ophthalmology. 2014 Mar;121(3):778-84. doi: 10.1016/j.ophtha.2013.09.041. Epub 2013 Dec 15.

43.

Incidence of visual improvement in uveitis cases with visual impairment caused by macular edema.

Levin MH, Pistilli M, Daniel E, Gangaputra SS, Nussenblatt RB, Rosenbaum JT, Suhler EB, Thorne JE, Foster CS, Jabs DA, Levy-Clarke GA, Kempen JH; Systemic Immunosuppressive Therapy for Eye Diseases Cohort Study.

Ophthalmology. 2014 Feb;121(2):588-95.e1. doi: 10.1016/j.ophtha.2013.09.023. Epub 2013 Dec 12.

44.

Fundus image diagnostic agreement in uveitis utilizing free and open source software.

Hsieh J, Honda AF, Suárez-Fariñas M, Samson CM, Kedhar S, Mauro J, Francis J, Badamo J, Diaz VA, Kempen JH, Latkany PA.

Can J Ophthalmol. 2013 Aug;48(4):227-34. doi: 10.1016/j.jcjo.2013.02.010.

45.

Marginal structural models for comparing alternative treatment strategies in ophthalmology using observational data.

Joffe MM, Pistilli M, Kempen JH.

Ophthalmic Epidemiol. 2013 Aug;20(4):197-200. doi: 10.3109/09286586.2013.792939. Epub 2013 Jul 2. No abstract available.

46.

Response of pediatric uveitis to tumor necrosis factor-α inhibitors.

Lerman MA, Burnham JM, Chang PY, Daniel E, Foster CS, Hennessy S, Jabs DA, Joffe MM, Kaçmaz RO, Levy-Clarke GA, Mills MD, Nussenblatt RB, Rosenbaum JT, Suhler EB, Thorne JE, Kempen JH.

J Rheumatol. 2013 Aug;40(8):1394-403. doi: 10.3899/jrheum.121180. Epub 2013 Jul 1.

47.

Risk of choroidal neovascularization among the uveitides.

Baxter SL, Pistilli M, Pujari SS, Liesegang TL, Suhler EB, Thorne JE, Foster CS, Jabs DA, Levy-Clarke GA, Nussenblatt RB, Rosenbaum JT, Kempen JH.

Am J Ophthalmol. 2013 Sep;156(3):468-477.e2. doi: 10.1016/j.ajo.2013.04.040. Epub 2013 Jun 21.

48.

Fluorescein angiography versus optical coherence tomography for diagnosis of uveitic macular edema.

Kempen JH, Sugar EA, Jaffe GJ, Acharya NR, Dunn JP, Elner SG, Lightman SL, Thorne JE, Vitale AT, Altaweel MM; Multicenter Uveitis Steroid Treatment (MUST) Trial Research Group.

Ophthalmology. 2013 Sep;120(9):1852-9. doi: 10.1016/j.ophtha.2013.01.069. Epub 2013 May 21.

49.

Risk of elevated intraocular pressure and glaucoma in patients with uveitis: results of the multicenter uveitis steroid treatment trial.

Friedman DS, Holbrook JT, Ansari H, Alexander J, Burke A, Reed SB, Katz J, Thorne JE, Lightman SL, Kempen JH; MUST Research Group.

Ophthalmology. 2013 Aug;120(8):1571-9. doi: 10.1016/j.ophtha.2013.01.025. Epub 2013 Apr 16.

50.

Peripapillary choroidal neovascularization in pars planitis.

Mehta S, Hariharan L, Ho AC, Kempen JH.

J Ophthalmic Inflamm Infect. 2013 Jan 15;3(1):13. doi: 10.1186/1869-5760-3-13.

Supplemental Content

Loading ...
Support Center